AstraZeneca investors will look past another strong set of quarterly results on Thursday to focus on the main issue ...

In a report released today, Emily Field from Barclays maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of ...

AstraZeneca scrapped plans for a £450 million UK vaccine plant after rejecting a £78 million government offer, citing ...

Pharmaceutical company AstraZeneca has cancelled a planned 450 million-pound investment in a vaccine manufacturing plant in ...

CORE EARNINGS PER SHARE: Core earnings per share are expected to rise to $2.07 from $1.45 the year prior, according to the same consensus. AstraZeneca's stock is up 7.9% since the start of 2024.

AstraZeneca is asking a court to immediately stop generic drugmakers from their plans to make and sell generic forms of ...

The U.K. government is defending its negotiations with AstraZeneca (AZN), after the pharmaceutical company dropped a planned $558M investment ...

In recognition of World Cancer Day 2025, AstraZeneca reaffirms its commitment to advancing early detection, innovative treatments, and holistic patient care under this year’s theme, “United by Unique.

AstraZeneca on Friday scrapped plans to invest 450 million pounds ($558.3 million) in its vaccine manufacturing plant in ...

It is a sign of its frustration felt within Britain's largest company that it has chosen to publicly contrast the new government with the last. Image: Rachel Reeves. Pic: PA AstraZeneca draws just ...

The firm scrapped its £450m investment despite the government's offer of support, the government says.

AstraZeneca PLC closed 15.78% below its 52-week high of £133.88, which the company achieved on September 3rd.